Skip to content
COMPOUNDING SIG: To 503B or Not to 503B: That is the Question?
DATE: WEDNESDAY, SEPTEMBER 30, 2026
TIME: 1:00 PM ET / 12 NOON CT / 11:00 AM MT / 10:00 AM PT
Should your pharmacy consider 503B outsourcing? What are the opportunities, costs, and regulatory considerations?
Join us for a practical discussion of the 503B outsourcing facility model and how it differs from traditional pharmacy compounding. We’ll explore the current 503B market, capital and operational requirements, regulatory differences, and important considerations for pharmacies evaluating whether 503B may be right for their business.
The discussion will also include a separate look at controlled substances and the additional regulatory requirements and considerations that apply.
Whether you are considering entering the 503B space, partnering with a 503B facility, or simply want to better understand the differences, this SIG will provide valuable insight to help you make informed decisions.
Join us for this informative and timely discussion on one of the important questions facing compounding pharmacies today.
Erik Tosh, RPh, FACA, was Vice President of Professional Services for Letco Medical prior to retiring in 2021. Erik has 47 years’ experience in health care, with the last 40 in pharmacy. His work experience includes hospital pharmacy, independent community pharmacy, and industry. His most rewarding accomplishment is his 47-year marriage to wife Sharon.
Join us for a high-level overview of key considerations for starting or transitioning to a 503B Outsourcing Facility. We will start with a fifteen to twenty minute overview of what is involved in starting an Outsourcing Facility. We encourage attendees to ask questions and share their own perspectives.
REGISTER HERE!
This meeting will not offer CE.
